The National Committee for Clinical Laboratory Standards has developed a proposed standard method for in vitro antifungal susceptibility testing of yeast isolates (National Committee for Clinical Laboratory Standards, document M27-P, 1992). In order for antifungal testing by the M27-P method to be accepted, reliable quality control (QC) performance criteria must be developed. In the present study, five laboratories tested 10 candidate QC strains 20 times each against three antifungal agents: amphotericin B, fluconazole, and 5-fluorocytosine. All sites conformed to the M27-P standards and used a common lot of tube dilution reagents and RPMI 1640 broth medium. Overall, 98% of MIC results with amphotericin B, 95% with fluconazole, and 92% with 5-fluorocytosine fell within the desired 3-log2 dilution range (mode + 1 log2 dilution). Excellent performance with all three antifungal agents was observed for six strains: Candida albicans ATCC 90028, Candida parapsilosis ATCC 90018, C. parapsilosis ATCC 22019, Candida krusei ATCC 6258, Candida tropicalis ATCC 750, and Saccharomyces cerevisiae ATCC 9763. With these strains, 3-log2 dilution ranges encompassing 94 to 100% of MICs for all three drugs were established. Additional studies with multiple lots of RPMI 1640 test medium will be required to establish definitive QC ranges.
The increased incidence of fungal infections, particularly those due to Candida spp. and other yeasts, has stimulated the use and development of an increasing number of antifungal agents including the broad-spectrum azoles, fluconazole, and itraconazole (1-3, 5, 6, 13-18, 21, 22, 30-32) . Unfortunately, the increase in the number of fungal infections and the extensive use of new and established antifungal agents have resulted in the emergence of fungal pathogens that appear resistant to antifungal therapy both clinically and in vitro (2, 7, 8, 11, 12, 14, 16, 23-29, 33, 34) . Several recent reports describing fluconazole treatment failures associated with elevated MICs serve to underscore these concerns (8, 16, 27, 29, 33, 34) . These observations have led to a perceived need for the development of a reliable means of assessing the in vitro susceptibility of fungal isolates to new and existing antifungal agents (11, 12, 24, (27) (28) (29) . The National Committee for Clinical Laboratory Standards (NCCLS) Subcommittee on Antifungal Susceptibility Tests has developed a proposed reference method for testing Candida spp. and other yeasts on the basis of the use of RPMI 1640 medium and a macrodilution broth format (NCCLS document M27-P) (20). The M27-P method has been shown to be reproducible among laboratories, and clinical correlations are now being established (8-11, 23, 24, 27-29) .
In order for antifungal susceptibility testing to be accepted and performed in clinical laboratories, reliable quality control (QC) performance criteria must be developed for all antifun-gal agents tested with the M27-P method. Although QC strains and reference ranges are listed in the M27-P document (20), they have not been evaluated according to the guidelines of the NCCLS M23-T2 document, which addresses the requirements for establishing QC limits (19) .
In the present multilaboratory study, we provide a more extensive evaluation of 10 candidate yeast QC strains, including four strains listed in document M27-P. These strains were tested against three antimicrobial agents with significant antifungal activity by the NCCLS M27-P reference method (20) isolate was skewed by 10 off-scale (>64 j,g/ml) results reported by a single laboratory. If the results from that laboratory were omitted, then 77 of the 80 MIC results for that isolate (96%) would be included in the 3-dilution range defined by the mode 1 log2 dilution (8.0 to 32 ,ug/ml). For 5FC, the mode ± 1 log2 dilution encompassed .90% of MICs (90 to 100%) for 8 of the 10 QC strains (Table 3) . For QC strain C. albicans ATCC 24433, the mode was between two adjacent dilution steps, resulting in a 4-log2 dilution QC range (i.e., 0.5 to 4.0 ,ug/ml) that included 97% of the MICs. The MIC distribution for the C. albicans ATCC 76615 isolate was bimodal, with peaks at 8.0 and >64 ,ug/ml. A broad 6-log2 dilution range (4.0 to >64 ,ug/ml) was required to include >95% of the MICs. Fifty-six percent of the off-scale (>64 jig/ml) values were contributed by a single laboratory.
A comparison of the MIC QC ranges obtained in the present study with those reported previously in the NCCLS M27-P document (20) for four of the candidate QC strains reveals only minor differences (Table 4 ). In general, the QC ranges for 5FC are 1 log2 dilution lower in the present study than the ranges reported in document M27-P.
Overall, 98% of the MIC results with amphotericin B, 95% with fluconazole, and 92% with 5FC fell within the desired 3-log2 dilution range (mode ± 1 log2 dilution) for In this study, we have followed the NCCLS document M23-T2 guidelines for developing QC parameters; however, because we are still in the process of identifying appropriate QC strains, this study deviates somewhat from the M23-T2 procedures in that only one lot of RPMI 1640 broth medium was used in all laboratories. An additional study using multiple lots of RPMI 1640 test medium will be required to establish definitive QC ranges in compliance with document M23-T2.
We have not attempted to qualify strains that are resistant to each of the three antifungal agents as possible QC organisms.
Isolates with well-defined mechanisms of resistance and stable resistance characteristics are not readily available for all antifungal agents. Putative resistant isolates may be most useful when incorporated into an indicator or challenge panel for use in the comparison and validation of in vitro susceptibility testing methods and not for QC purposes.
In conclusion, we have taken an additional step in the standardization of antifungal susceptibility testing. We have identified candidate QC isolates that provide a broader range of species and on-scale MICs for the quality control testing of three antifungal agents. The MIC QC limits proposed in this report must be considered tentative until confirmed by an additional multisite study using different lots of RPMI test medium. In the interim, these results should be useful in assisting interested laboratories in establishing reliable antifungal susceptibility testing by the NCCLS M27-P proposed standard method.
